Shots:
- Rapport Therapeutics has granted Tenacia exclusive rights to develop & commercialize RAP-219 in Greater China across indications, incl. focal onset seizures (FOS) & bipolar mania, with Rapport retaining rights in other territories
- As per the deal, Rapport will receive $20M upfront & ~$308M in development & commercialization milestones & other payments, plus mid-single digits to mid-teens tiered royalties on net sales in Greater China
- RAP-219 is a TARPγ8-specific AMPA receptor negative allosteric modulator, which will be studied in two global P-III trials for FOS, expected to initiate in Q2’26
Ref: Tenacia  |  Image: Tenacia & Rapport  | Press Release
Related News: GSK Licenses Linerixibat’s Global Rights to Alfasigma in ~$690M Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
